The efficacy of one-stage artificial dermis and skin grafting was tested in a nude rat model. Reconstruction with artificial dermis is usually a two-stage procedure with 2-to 3-week intermission. If one-stage use of artificial dermis and split-thickness skin grafting are effective, the overall burden on patients and the medical cost will markedly decrease.
Introduction
Bilayer medical devices for covering skin defects are referred to as "artificial dermis".
Artificial dermis consisting of highly organized porous collagen and other amino acids as a scaffold induces dermis regeneration in the case of full-thickness skin defects.
Artificial dermis, a dermal regeneration template, has been used effectively in acute and reconstructive surgery and this has now been extended to chronic wounds (1) . It provides optimal dermal wound bed preparation as regenerated skin with extensive formation of rete ridges and capillary loops but with the absence of skin appendages (2) and is ready for relatively thinner subsequent skin grafting; thus, donor site morbidity is minimized. This low donor site morbidity is especially beneficial for large skin defects in children, who usually lack sufficient donor skin. Several combined procedures have been attempted in reconstruction with artificial dermis including cultured autologous keratinocytes (3) and composite biocompatible epidermal graft, which composes autologous keratinocytes cultured over a hyaluroate-derived membrane using dermal fibroblasts as a feeder layer (4) ; however, the use of cultured cells yields inconsistent graft take rates. Thus, two-stage surgery is the standard for large skin defect coverage using artificial dermis. In two-stage surgery, secondary split-thickness skin grafting is undertaken at 13 to 19 days (5), 14 to 21 days (6), 21 days (7) or 28 days (8) depending on the product or the patients' systemic and local wound conditions. Even though the use of artificial dermis in reconstruction avoids greater surgeries such as free flaps or distant flaps and may bring about a better scar outcome in terms of softness, pliability and stratum corneum function of the epidermis (5), the clinical application of artificial dermis is rather limited due to the higher cost of using this procedure. Despite the product cost, there are indirect costs due to increased hospitalization, requiring two independent surgeries per case, the risk of a higher infection rate and lengthy dressing changes (9) . In an elderly person with a poor systemic condition, one-stage skin grafting and cellular human dermis over the exposed skull demonstrated an excellent outcome (10) and the use of a dermal matrix based on bovine collagen I, III, and V, elastin hydrolysate and split-thickness skin grafting was safe and feasible, demonstrating markedly better clinical results in elasticity (11) .
We therefore sought to investigate the efficacy of one-stage simultaneous skin grafting and artificial dermis in the reconstruction of skin defects using a nude rat model, and fixing a frame device to avoid skin contracture from the surrounding skin in the course of wound healing with an angiogenic growth factor. In this one-stage procedure, the artificial dermis is made in a monolayer devoid of the outer silicone membrane In order to effectively facilitate the graft take by basic fibroblast growth factor, the only angiogenic factor available currently in Japan, which accelerates burn wound skin graft healing (12) and is used alone in second degree burns (13) , combined use with artificial dermis was also tested.
Materials and Methods

Animals
A total of 78 male F344/NJCl-rnu nude rats (CLEA JAPAN, Inc., Tokyo, Japan), deficient in T-cell function, aged 7 to 9 weeks, weighing 150-210 g, were used in this experiment, and housed in the Laboratory Animal Center for Biomedical Research, Nagasaki University School of Medicine, Nagasaki, Japan. They were handled according to the guidelines established for animal care at the center and the protocol was approved by the institutional animal care and use committee (IACUC) of Nagasaki University (#1008030872). Each rat had free access to sterile water and standard rodent soft chow ad libitum.
Study Design
Rats were divided into the following groups:
1. Group 1 (n = 18): split-thickness skin grafting alone (STSG), 2. Group 2 (n = 21): one-stage; simultaneous, artificial dermis and splitthickness skin grafting (AD + STSG), 3 . Group 3 (n = 18): two-staged; artificial dermis grafting alone, and 2 weeks later: split-thickness skin grafting [AD + STSG(2W)], 4. Group 4 (n=21): one-staged; simultaneous, artificial dermis, basic fibroblast growth factor (bFGF), and split-thickness skin grafting (AD + bFGF + STSG).
The parameters to be evaluated were; the macroscopic aspect of the grafts through serial photography, the measurement and calculation of graft take rates, analysis of the measurements obtained with the Cutometer, and biopsy taken for histological, immunohistochemical, zymographic, RT-PCR, and electron microscopic analyses (Table   1) .
Serial photographs were taken 3 days, 1 week, 2 weeks, 3 weeks and at 3 months, respectively, after the initial procedure, of all specimens.
Graft take rates were determined at 1 week, 2 weeks, 3 weeks and at 3 months for all specimens.
Cutometer measurements were performed at 3 weeks and 3 months, from 6 specimens of each group each time.
From the middle and healthy part of the grafted area, samples were taken at 3 days (n = 6; 3 specimens from groups 2 and 4), 1 week (6 specimens of each group from all four groups), 3 weeks (6 specimens of each group from all four groups), and at 3 months (6 specimens of each group from all four groups). After taking samples, animals were euthanized ( Table 1) .
As an internal control, the contraction rates of the graft "beds" were measured at 1 week and 2 weeks.
Surgical Procedure
Animals were anesthetized with a 40 mg/kg body weight intra-peritoneal injection of sodium pentobarbital, (Somnopenthyl; Kyoritsu Seiyaku, Tokyo, Japan). All procedures were performed under sterile conditions. A circular (2.5 cm diameter, thus 4.9 cm 2 ), full-thickness skin defect was created on the back of each rat at one side of the spine. Split-thickness skin grafts were harvested with an electric dermatome (Zimmer; Zimmer Orthopaedic Surgical Products, Inc., Warsaw, IN, USA) from the opposite side of the rat's back, and an intermediate split-thickness skin graft (15/1,000-inch) was implanted into the same-sized full-thickness skin defect and fixed on its border to the full-thickness surrounding skin with non-absorbable sutures.
An artificial dermis, Terudermis (Olympus Terumo Biomaterials Corp., Tokyo, Japan), is a collagen monolayer type, 2 mm thick, is made of a low antigenic fibrillar atelocollagen and heat-denatured atelocollagen cross-linked dehydrothermally, produced from a calf tendon collagen, eliminated the telopeptide by a preparation of protease. A 1:1 mesh type of "drainage" type, artificial dermis, collagen monolayer type was placed to fit and cover the entire surface of the skin defect and skin grafting.
For group 3, 2 weeks after grafting with artificial dermis alone, an STSG was harvested from the opposite site of the graft on the back and placed into an STSG in the same way.
To prevent wound closure from the surrounding skin, and to protect, isolate, and monitor the evolution precisely, polypropylene rings, 2.5 cm in diameter, with a total inner area of 4.9 cm², were designed from commercially available and highly standardized pet bottles. The rings were fixed on top and covering the full extension of the graft bed by non-absorbable sutures (mono-nylon 4-0; Ethicon; Ethicon, Inc., Somerville, NJ, USA).
Ointment-impregnated gauze (Sofra-Tulle Dressing 1%; Hoechst Marion Roussel Ltd., Germany) was applied on top of the grafts and inside the polypropylene ring in all cases, removed after 7 days and exchanged when necessary. Polypropylene rings were closed with their respective perforated plastic caps.
All animals were euthanized by anesthetic overdose.
bFGF (Trafermin, Fiblast Spray)
Genetically recombinant bFGF (Fiblast Spray; Kaken Pharmaceutical Co., Ltd., Tokyo, Japan) was sprayed onto the surface of the full-skin defect after the artificial dermis was placed in group 4 specimens at day 0. The concentration of the bFGF spray was 1µg/cm² in the graft bed and was prepared according to the manufacturer's recommendations.
Photographic monitoring of take rate
Serial photographs of the grafts were taken by a digital camera (Olympus SH-25MR, Tokyo, Japan) at 3 days, 1 week, 2 weeks, 3 weeks and at 3 months, respectively, for all specimens, and when taking a photograph, the axis to the object (grafted area) was adjusted to be perpendicular.
Analysis of graft take and contraction rate
The measurement tool of Adobe Photoshop CS5 Extended software was applied to the relative areas of the graft take and contraction, and the graft take rate (%) was obtained by the visible graft take area divided by the initial total implantation area; the results were multiplied by 100 and expressed as a percentage.
The contraction rate was determined by subtracting the initial grafted area including the graft take and non-take areas divided by the initial area size of 4.9 cm 2 from 1, and multiplied by 100 and expressed as a percentage. Measurements were taken by 3 independent observers, averaged, and the means were determined. Values obtained were used for further statistical comparison and analysis.
Cutometer analysis
A Cutometer MPA 580 (Courage + Khazaka Electronic GmbH, Cologne, Germany) was used to evaluate skin elasticity parameters at 3 weeks and 3 months. The
Cutometer is able to measure vertical deformation of the skin by suctioning into a round probe, 6 mm in diameter. Measurements were taken in mode 1. A vacuum load of 500 mbar was used over the healthy graft's surface for 2 seconds (on-time), followed by a normal pressure (relaxation) of 2 seconds (off-time). Each measurement was repeated 4 times in 2 cycles, taken from the center of the graft and assessed at 25ºC room temperature, and 50% humidity with air conditioning. Two parameters of the Cutometer were used in this investigation. The Uf (depicted as R0) stands for the maximal skin extension deformation at the end of the vacuum period (skin firmness); Ur/Uf (R7) stands for the ratio of the retraction (Ur) to the maximal extension (Uf) and reflects the elasticity of the measured tissues.
Histology
Tissue samples were resected from the center of the grafts at 3 days, 1 week, 3 weeks, and 3 months, respectively, and subjected to immediate fixation with 10% buffered formalin, then paraffin-embedded and sectioned at 4 µm thickness for hematoxylin and eosin (H & E) staining and further examination and analysis by light microscopy.
Dermal/Artificial-Dermal thickness Dermal thickness was measured from each slide (all specimens), at a magnification of 25×, from 5 different, randomly selected, fields per specimen, from the epidermal-dermal junction to the dermal-subdermal junction, using AxioVision 4.8 software (Carl Zeiss MicroImaging, GmbH, 07740, Jena, Germany), at the determined given time points.
Results, expressed in micrometers (µm), were used for further statistical analysis.
Number of fibroblasts in the dermis/artificial dermis
The number of dermal fibroblasts was also counted from 5 randomly selected fields (5 specimens of each group), taken from a half-point line traced on the full-thickness dermal layer, equivalent in all cases, at a magnification of 630×, with H&E staining using the aforementioned software. Results of the fibroblast count per field were used for statistical analysis.
Macrophage assessment with F4/80
Representative paraffin-embedded tissue samples of each group (2 tissue samples per group) at 1 week, 3 weeks, and 3 months were taken in order to determine macrophage presence and distribution analysis using the F4/80 marker. A Rabbit polyclonal antibody to F4/80, with reactivity to rat (Anti-F4/80 antibody, ab74383, Abcam Ltd., Cambridge, UK), was used.
After deparaffinization of the tissue samples with xylene, 100% ethanol, 90% ethanol, 80% ethanol, and ddH₂O, respectively, antigen was retrieved in microwave for 20 minutes, slides were washed in ddH₂O for 10 min on a shaker, and then internal peroxidase activity was blocked with 3% H₂O₂ for 10 min. Sections were washed in ddH₂O and PBS respectively, incubated with blocking solution (1% BSA) for 30 min at room temperature, and then the primary antibody was added with blocking solution at a concentration of 1:100 (1% BSA) for 1 hour at room temperature. Slides were washed with PBS, followed by incubation with the secondary antibody (Goat polyclonal Secondary Antibody to Rabbit IgG -H&L (HRP), ab6721, Abcam Ltd., Cambridge, UK) for 2 hours at room temperature. DAB (diaminobenzidine) was added for chromogen colorization until it turned brown over 3-20 min.
The results were evaluated using a strong positive, weak positive and negative staining/reactivity scale as determined by trained experienced pathologists.
Alpha Smooth Muscle Actin (α-SMA)
Representative tissue samples of each group (2 tissue samples per group) at 1 week, 3 weeks, and 3 months were taken in order to determine α-SMA (α-smooth muscle actin).
A rabbit monoclonal antibody, to α-SMA, was used (Epitomics, Inc., Burlingame, CA, USA).
After deparaffinization of the tissue samples with xylene, 100% ethanol, 90% ethanol, 80% ethanol, and ddH2O, respectively, slides were washed in PBS (protein blocking solution) for 5 min on a shaker, and then internal peroxidase activity was blocked with 3% H2O2 for 15 min. Sections were washed in PBS for 5 min, 3 consecutive times, incubated with blocking solution (5% BSA) for 15 min at room temperature, and then the primary antibody was added with blocking solution at a concentration of 1:1000 (5% BSA) and left overnight at 4˚C. The next day, slides were washed with PBS for 5 min, 3 times, followed by incubation with the secondary antibody (Universal goat anti-mouse IgG biotinylated secondary antibody) for 60 min at room temperature. DAB weeks, and 3 months were taken in order to determine MMP-2 (matrix metalloproteinase-2) reactivity to mouse/rat MMP-2 antibody (Antigen Affinity-purified Polyclonal Goat IgG, Catalog Number: AF1488, R&D Systems).
After deparaffinization of the tissue samples with xylene, 100% ethanol, 90% ethanol, 80% ethanol, and ddH2O, respectively, antigen was retrieved with pepsin for 30 min at 37°C, then washed in ddH2O for 5 min twice (on shaker), and proteinase K was added for 6 min at room temperature. Slides were washed in PBS for 5 min (on a shaker) and internal peroxidase activity was blocked with 3% H2O2 for 15 min. Sections were washed in PBS for 5 min, 3 times, and incubated with blocking solution (BSA 1%) for 30 minutes at room temperature. Primary antibody was added at a 1:1 concentration with BSA 1%
and left overnight at 4˚C. The next day, slides were incubated with the secondary antibody for 1 hour at room temperature. DAB was added for chromogen colorization until it turned brown over 3-20 minutes.
The results were evaluated using a strong positive, weak positive and negative staining/reactivity scale as determined by trained pathologists.
Gelatin Zymography
Gelatinolytic activity of MMP-2 was determined by zymography.
Fresh representative skin samples (2 samples per group), corresponding to 1 week and 3 weeks, were immediately frozen in dry ice after harvested, and stored at -80°C. Proteins were extracted with lysis buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Nonidet P-40 and 0.05% sodium dodecyl sulfate (SDS)). The supernatant was collected after centrifugation at 15,000 rpm for 10min at 4°C, and the protein concentration was quantified by BCA assay (Pierce® BCA Protein Assay Kit, Pierce Biotechnology, Rockford, IL, USA).
Protein samples (40 µg) were then re-suspended in SDS-polyacrylamide gel electrophoresis sample buffer, without beta-mercaptoethanol and were loaded on polyacrylamide gels containing 0.1% gelatin (Sigma). After electrophoresis, the gels were washed with wash buffer (10 mM Tris-HCl, pH 7.4, 2% Triton X-100) for 1 hour, equilibrated in 10 mM Tris-HCl, pH 7.4, and incubated in reaction buffer (10 mM TrisHCl, pH 7.4, 5mM CaCl2, 1% Triton X-100) in a CO₂ incubator overnight. Then, the gels were stained with 0.2% Coomassie Brilliant Blue and de-stained in a solution of methanol and acetic acid.
Gels were photographed and pictures were converted into grayscale and assessed for quantitative analysis using Adobe Photoshop CS5 Extended software, for band intensity determination using color densitometry in pixels as a relative unit of measure for comparison. Results were interpreted adopting a scale of strongly positive, weakly positive and negative, and focus was centered on the band of 72 kDa (kiloDalton); corresponding to MMP-2.
Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for MMP-2
Total RNA was extracted using an RNeasy lipid tissue mini kit (QIAGEN, Tokyo, Japan) according to the manufacturer's instruction. A measure of 500 ng of total RNA was reverse transcribed using a High-capacity RNA-to-cDNA kit (Applied Biosystems, Life Technologies Japan, Tokyo, Japan). The following PCR amplification was carried out in a Thermal Cycler Dice Real-time system using SYBR Premix Ex Taq II (TaKaRa Bio, Ohtsu, Japan). β-actin was used as an internal control. The cycle threshold value, which was determined using second derivative, was used to calculate the normalized expression of the indicated genes using the Q-Gene software (14) .
The primer sequence used for MMP-2 was 5'-CCG AGG ACT ATG ACC GGG ATA A-3', and 5'-CTT GTT GCC CAG GAA AGT GAA G-3' (15) (16) (17) , and for β-actin 5'-CTG AAC CCT AAG GCC AAC CGT G-3' and 5'-GGC ATA CAG GGA CAG CAC AGC C-3'(18).
Electron Microscopy
Tissue samples were taken, as described previously (at 1 week, 3 weeks, and 3 months), from the center of the grafts and fixed in 2.5% buffered glutaraldehyde in order to be examined by electron microscopy.
Statistical Analysis
All statistical analyses were conducted with IBM SPSS 19 software. All data are expressed as the mean ± SD. Data between groups were evaluated by one-way analysis of variance (ANOVA), followed by Bonferroni post-hoc tests for multiple comparisons. A value of p <0.05 was considered significant.
Results
In groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG (2W)], and 4 (AD+bFGF+STSG), there were no animal deaths throughout experiment and all animals were healthy.
Graft Take Rate
The mean graft take rates at 1 week were 84 ± 9.0 %, 86 ± 5.9 %, 68 ± 8.1 %, and 83 ± 6.4 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), respectively. Group 3 was significantly lower than the rest of the groups (p <0.001), and group 2 was significantly greater than group 4 (p = 0.02).
At 2 weeks, the mean percentages of graft take rates were 88 ± 8.1 %, 81 ± 9.8 %, 74 ± 7.9 %, and 78 ± 8.3 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), respectively. Group 1 was significantly greater than the other groups (p <0.001), and group 2 was significantly greater than group 3 (p <0.001).
At 3 weeks the mean graft take rates were 99 ± 1.2 %, 93 ± 4.2 %, 87 ± 10.6 %, and 92 At 3 months all graft take rates were 100% in all groups.
Contraction Rate
The mean percentages of grafting contraction at 1 week were 21 ± 6.8 %, 24 ± 10.5 %, 49 ± 11.5 %, and 26 ± 8. There was a steep increase in α-SMA expression between 1 and 3 weeks (Figure 6 ).
At 3 months all groups had a similar number of dermal vessels. Overall, the number of vessels in all groups was higher at 3 weeks, followed by 3 months and 1 week, respectively. (Table 3 ).
Gelatin Zymography
At the 72 kDa (kiloDalton) band corresponding to MMP-2 (Gelatinase A), the activity at When the total expression was compared between groups in regards of time, it showed to be higher at 1 week.
Transmission Electron Microscopy
At 3 weeks, electron microscopy of group 4, one-stage skin grafting with artificial dermis and bFGF, demonstrated the most evenly distributed fibrils in the entire dermis.
In contrast, the appearance in group 3 denotes more inflammatory invading cells, the appearance in group 2 demonstrated denser fibrils with more open gaps, and the appearance in group 1 demonstrated a stronger dermal-epidermal junction with scant dermal fibrils ( Figure 11 ). By 3 months, electron microscopy from all groups showed that they had matured.
Discussion
Skin grafting experiments using rodents are sometimes a concern as the micro-skin graft results in greater contraction of the wound area (19) . Contraction of the wound area is an integral part of the wound bed, the interface between the skin and graft. Thus, we adopted a system to prevent wound closure from the surrounding tissue as well as to observe the natural progress of the interface between the graft and wound bed and the graft itself.
A similar system using Matriderm® and the dermal part of Integra® but different in study design was used to clarify the engraftment rate and vascularization in these two artificial dermis' using a neonatal Wistar rat epidermis over a nude rat recipient (20) . In this comparative experimental study, however, neonatal epidermal skin grafting was performed 1 or 2 weeks after transferring the artificial dermis. Matriderm® was superior to the dermal part of Integra® at 1 week in terms of graft take, but the graft take at 2 weeks after the 2 week-waiting period of Integra® demonstrated the best among 4 groups.
Matriderm® as a transport carrier of cultured keratinocytes and melanocytes successfully demonstrated viable, metabolically active keratinocytes and melanocytes and resulted in pigmented reconstructed epidermis in vitro (21) .
In our experiment, we tested the efficacy of one-stage artificial dermis and skin grafting and this procedure may reduce the frequency of surgery, diminishing the intermission between the artificial dermis and split-thickness skin grafting and thus shortening the patients' treatment days and overall medical costs. The graft rate sequentially improved in groups 1 and 3 from 1 week to 3 months, whereas the graft rates in groups 2 and 4, which had artificial dermis with or without bFGF in one step, demonstrated sagging at 2 weeks. By 3 months, graft take rates in all groups seemed to be 100% because the tissue that had not taken had fallen off and the surrounding tissue had contracted to cover the defects. The contraction rate in group 3 was significantly greater than in groups 2 and 4 at 1 week and group 2 at 2 weeks. As the contraction rate increases, the graft seems to be masked by surrounding tissue replacing the original defect, and so the graft take rate is relatively increased. The dermal or artificial dermal thickness increases 2-fold between 1 week and 3 weeks in group 2 but decreases 20 % between 1 week and 3 weeks in group 3, while it is almost consistent from day 3, 1 week and 3 weeks in group 4. Skin graft survival with insertion of artificial dermis is determined at day 14 (22) .
Thus, gross and histological evaluations at 2 weeks and 3 weeks are reasonable. Fibroblast counting at 3 weeks in group 4 was statistically greater than in group 3 and the immunohistochemical expression of α-SMA was greatest in the number of cells and intensity. The immunohistochemistry of F4/80 demonstrated the gradual regression from 1 week, 3 weeks to 3 months probably due to the decrease or attenuation of macrophages in the wound healing process. α-SMA-positive and vessel-forming cells are considered to be mature blood vessels, thus indicating functional blood vessels (23) . The dermal tissue from group 4 in the 3 weeks demonstrated the highest expression of α-SMA, thus showing highly and more matured blood vessels in the dermis. CD31, reflecting neo-vessel formation, expressed greatest in Group 4, with bFGF than other groups and reaches its peak at 3 weeks in all groups and decreases at 3 months.
Tissue elasticity denoted by R7 obtained by Cutometer in group 4 demonstrated significantly 27.5% more elasticity than group 2, the difference being no bFGF; thus, bFGF affects elasticity in the one-stage artificial dermis and skin grafting model. In our previous clinical measurement, although it was measured in human clinical cases, and used a different procedure of two-stage skin grafting and different measurement device, a durometer, of bFGF-treated artificial dermis and skin grafting showed more than 50% better tissue hardness (5). The tissue extensibility denoted by R0 is determined by the dermal thickness; thus, the thinnest tissue from group 1 demonstrated the greatest value and was especially more significantly extensible than group 2.
The expression of matrix metalloproteinase-2 (MMP-2) was somewhat weak at 3 weeks, except in group 3, in which the intensity was stronger than in other groups. MMP-2 expression was inversely correlated with concentrated collagen hydrogel in an in vitro assay (24) , and the effective collagen content in group 3 may be attenuated compared to other groups.
Also in immunohistochemistry, MMP-2 levels gradually increase from 1 week, 3 weeks to 3 months. MMP-2 is constitutively synthesized (25) . The expression levels of MMP-2 between RT-PCR and gelatin zymography are different. The values of Group 3, which is staged skin grafting demonstrated higher in transcript levels and lower in gelatinolytic activity when compared to other groups both; at 1 week and 3 weeks. The posttranscriptional mRNA stabilization of MMP-2 is controlled, and the protein level is not reflected (26) . Apparently in Group 3, the tissue inflammation is prolonged due to less graft take and more continued wound healing process due to staged skin grafting.
Electron microscopic findings at 3 weeks showed comparable functional elasticity and light microscopic findings to group 4, so one-stage artificial dermis and split-thickness skin grafting with bFGF may bring about the most elasticity, maturity of fibroblasts and more blood supply as the fibrils are organized, with less invasive cells.
We therefore reach the conclusion that one-stage artificial dermis and split-thickness skin grafting has a graft take rate almost as high as split-thickness skin grafting alone and with more fibroblasts and blood vessels and greater elasticity. Thus, this method is recommended because it is faster, easier, and less invasive, with shorter hospitalization.
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